A 2022 Wilderness Medical Society convened a panel to review the literature and develop evidence-based clinical practice guidelines on the treatment of anaphylaxis. The guideline discussed epinephrine auto-injectors (EAIs), prefilled syringes, and epinephrine manually drawn from vials or ampules, noting that auto-injectors eliminate the need to draw up medication and may reduce dosing errors, whereas vial- or ampule-based administration is less expensive but may be associated with delays and operator errors during dose calculation and preparation. The guideline concluded that device selection should be based on factors such as cost, training, and safety, but it did not compare outcomes of inpatient anaphylaxis management with auto-injectors versus epinephrine prepared from concentrated vials, nor did it evaluate pharmacy compounding practices. [1]
A 2017 scoping review comparing EAIs with epinephrine drawn into syringes identified substantial knowledge gaps and found that dosing and route-of-administration errors occurred more frequently with manually prepared epinephrine, including reports of inadvertent intravenous administration and associated adverse events. In contrast, EAIs were generally associated with fewer potentially life-threatening errors, although device-related injuries and administration mistakes were also reported. The review suggested that hospitals consider these safety and cost tradeoffs when selecting an approach but did not directly compare clinical outcomes of inpatient anaphylaxis treatment using auto-injectors versus compounded or manually prepared epinephrine. [2]
Additional hospital-focused review articles described several approaches to epinephrine storage and administration, including stocking auto-injectors, drawing doses from vials or ampules at the time of use, and maintaining pharmacy-prepared kits containing vials and administration supplies. One report described an inpatient hospital system that transitioned to epinephrine kits prepared and distributed by the pharmacy to improve speed and ease of administration, but this was based on simulation experience rather than a clinical comparison of patient outcomes. The authors also discussed compounded prefilled syringes as a potential option, noting limitations related to storage requirements and the lack of specific guidance for intramuscular use. [3], [4]
While not specific to inpatient settings, a practice parameter update published in 2023, assessed key clinical inquiries regarding the management of anaphylaxis. Preference for vials vs auto-injector pens was not discussed in detail, but regarding accessibility, the review references a 2020 study published by the Canadian Agency for Drugs and Technologies in Health. Within this study, the organization could not identify any studies that compared auto-injectors to manually administered compounded epinephrine. [5, 6]
Per a 2015 American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI) practice parameter update, auto-injectors remain the preferred method for administering epinephrine to children weighing less than 15 kg (33 pounds), despite being technically off-label for this weight group. This recommendation is made because using an auto-injector is safer and provides a more accurate dose than having a caregiver draw epinephrine from a vial, a process prone to dangerous errors. The guidance is further supported by the fact that the optimal dose of epinephrine is not definitively established, making the proven safety and accuracy of an auto-injector the more prudent choice. [7]
A 2017 article explores the critical role of epinephrine in managing anaphylactic emergencies, particularly focusing on the choice between autoinjectors and 1-mg vials or ampoules. Epinephrine autoinjectors are emphasized for their accessibility and ease of use in community settings, providing a vital resource for those at risk. The article draws attention to significant risks associated with using 1-mg ampoules or vials, such as wrong-dose and wrong-route errors. The complexity of drawing up and administering a precise dose during stressful emergency situations can lead to potentially harmful consequences, including inadvertent intravenous administration. Within the context of healthcare settings, the author advocates for the deployment of epinephrine autoinjectors to mitigate these risks. Nevertheless, challenges persist, including the financial implications of stocking autoinjectors and the need for comprehensive training and retraining of healthcare professionals to ensure proper usage and readiness in the event of an anaphylactic reaction. [8]
A 2025 review mentions supporting studies that suggest intramuscular (IM) administration of epinephrine by auto-injectors is found to be substantially better at delivering therapeutically relevant doses with significantly higher plasma adrenaline compared to normal syringe injections. Despite being low-cost and low-tech, use of ampules, syringes, and training for proper needle technique can lead to struggles for prompt dosing and accuracy. Healthcare providers, in particular, demonstrated inconsistencies in epinephrine concentrations when challenged in a published study to draw doses promptly from ampoules. Extreme cases like refractory anaphylaxis may necessitate intravenous (IV) epinephrine, but would require careful supervision under skilled healthcare practitioners to monitor its effects within the hospital, rather than an outpatient clinic. [9]